key: cord-0935497-8f8tkpoc
authors: Kolesar, Jill M; Vermeulen, Lee C
title: Precision medicine: Opportunities for health-system pharmacists
date: 2021-03-10
journal: Am J Health Syst Pharm
DOI: 10.1093/ajhp/zxab084
sha: 3dc94441b64ff9b8b06801323e7d1c4b0429b249
doc_id: 935497
cord_uid: 8f8tkpoc

In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

today, precision medicine should be considered any care that is guided by individual patient characteristics, including genetic characteristics and other factors such as diet and lifestyle, that maximize treatment benefits while minimizing adverse effects and cost.

In 2015, the United States embarked on a national research agenda to advance precision medicine. 2 A major component of this initiative is the All of Us study, which is establishing a cohort of 1 million individuals with full genomic sequencing and extensive surveys of lifestyle, health, and family medical history. 3 While the focus of the All of Us study is research, a second initiative, the Cancer Moonshot, recognizes that precision medicine is already a clinical reality for many patients with cancer and focuses on accelerating clinical use of precision medicine. The 21st Century Cures Act was passed by Congress in December 2016, authorizing $1.8 billion in funding for the Cancer Moonshot and $215 million for the All of Us study. 4 Pharmacists have a long-standing interest in optimizing care by individualizing therapy. Pharmacokinetic dose adjustment is an early example of precision medicine, pioneered by clinical pharmacists. As far back as 1998, ASHP published a statement that pharmacists' responsibilities included "designing patient-specific drug dosage regimens based on pharmacokinetic characteristics of the drug product." 5 At the ASHP Pharmacy Practice Model Summit, at least 10 recommendations related to pharmacogenomics and A c c e p t e d M a n u s c r i p t pharmacy practice were made. 6 Given the anticipated transformative nature of the current efforts in precision medicine, the purpose of this article is to describe current pharmacist roles in genomic aspects of precision medicine, to assess barriers and facilitators to implementing precision medicine, and to discuss emerging trends likely to impact health systems.

Current pharmacist practice models in germline, or hereditary, pharmacogenomics.

In the United States, few academic medical centers and even fewer community pharmacies have implemented pharmacogenomics programs led by pharmacists, despite pioneering programs being in existence as early as 2007. 7 Characteristics across successful programs include preemptive and indication-triggered testing with a focus on well-defined drug-gene pairs, commonly focusing on clopidrogel, warfarin, and thiopurines. 6 Road maps for implementing pharmacogenomics into clinical practice include addressing educational gaps, engaging a multidisciplinary team, garnering strong institutional support (including informatics support), and tracking of quality metrics. Securing the resources needed to launch these programs remains a challenge, as most pioneering programs used research grant funds to implement pharmacogenomic testing and therapeutic alternatives to clopidrogel and warfarin are readily available. Overcoming logistical hurdles, particularly obtaining test results quickly at the time of prescribing, also remains a challenge. 6 Barriers to implementing germline pharmacogenomics. Currently, there are hundreds of medications with genomic information in their Food and Drug Administration (FDA)-approved labels or in practice guidelines, 8 and a federally funded clinical trials network has been created to support the implementation of genomics. 9 Despite these efforts, pharmacogenomic testing is not routinely performed in most institutions. An illustrative case is that of codeine and cytochrome P-450 (CYP) isozyme 2D6-guided dosing, A c c e p t e d M a n u s c r i p t whereby instead of implementing guided dosing prior to codeine use, clinical workarounds, including contraindicating use and recommending alternative agents, are currently recommended. Codeine is the oral prodrug of morphine, and CYP2D6 is required to convert codeine to morphine. 10 Patients who are CYP2D6 rapid or ultrarapid metabolizers are able to convert codeine to morphine faster than their counterparts with normal CYP2D6 function, and they are at increased risk for adverse effects caused by excessive exposure to morphine. After the publication of a number of case reports [11] [12] [13] [14] of respiratory depression and deaths associated with codeine in CYP2D6 rapid and ultrarapid metabolizers, FDA reviewed data collected in its Adverse Event Reporting System from 1965 to 2015 and identified 24 codeine-associated deaths, prompting FDA 15 to contraindicate codeine use in children under 12 years of age. This move was supported by the American Academy of Pediatrics, which recommended against CYP2D6-guided genotyping, citing insufficient evidence to support the practice, and suggested use of alternative agents for pain management in children. 16 In addition, in a prospective study evaluating CYP2D6 genotyping and codeine use, providers were likely to prescribe alternatives for ultrarapid and rapid metabolizers, but uncontrolled pain was more frequent in poor metabolizers. 17 Major barriers to implementation of pharmacogenomic testing include a lack of provider and administration buy-in, logistical challenges around testing, and poor reimbursement. 6 Both buy-in and reimbursement are heavily influenced by evidence, typically in the form of prospective randomized trials, demonstrating clinical benefit with meaningful financial implications, which are important to providers and payers. Currently, there is strong evidence associating particular genotypes with drug outcomes, and guidelines developed and published by the Clinical Pharmacogenetics Implementation Consortium (CPIC) discuss appropriate dosing adjustment and use of alternative agents for A c c e p t e d M a n u s c r i p t specific genotypes. 8 However, there is limited data to suggest that performing genotyping, in and of itself, improves overall patient outcomes, and the CPIC guidelines stop short of recommending genotyping, instead focusing on dose adjustment or the substitution of alternative agents if a patient has a known problematic genotype. In other words, there is strong evidence for many drug-gene pairs that for an individual patient, with a variant genotype, dose adjustment or drug substitution improves individual patient outcomes.

However, with the exception of TPMT genotyping and 6-MP dose adjustment, 18 there is limited evidence to suggest that population-level or indication-specific genotyping improves care over standard approaches. Even when evidence is sufficient to gain the support of clinicians and administrators, implementing pharmacogenetic testing requires resources and motivation, and using an alternative therapy that is not affected by genetic anomalies, like codeine, is often simply an easier therapeutic path.

Direct-to -consumer (DTC) pharmacogenetic testing may overcome barriers associated with implementing pharmacogenomics, as a patient presenting to a provider with results in hand eliminates the buy-in, reimbursement, and logistical challenges discussed previously. DTC testing is available outside the health system, is paid for by the patient, and does not require a physician order. While there are concerns related to test accuracy and clinical utility, the DTC testing industry is experiencing strong growth. 19 Population genotyping efforts by health systems may also overcome barriers to pharmacogenetic testing. While currently focused on disease predisposition genes, Geisinger Health has established a cohort of more than 200,000 individuals with whole exome sequencing data. 21 The cohort (formed under the MyCode Community Health Initiative) was established for research purposes; however, results are returned to individual patients if they have an alteration in one of 59 genes associated with known disease risk, as recommended by American College of Medical Genetics and Genomics guidelines. 22 Results are communicated to both the patient and the treating physician, who determine the follow-up plan. Geisinger is not currently reporting pharmacogenetic data to the patient, pharmacist, or physician; however, given that whole exome sequencing is being performed, those data exist.

Cancer is unique in that somatic mutations, occurring only in the cancer cell, are both the cause of the disease and a therapeutic target. In headto-head clinical trials comparing targeted therapies to standard chemotherapy, targeted therapies have been found to be both more effective and to have fewer adverse effects than other forms of treatment. 23, 24 This approach has revolutionized cancer drug development. In 2019 alone, of the 48 new drugs approved by FDA, 9 were new anticancer agents and all but one were targeted therapies and indicated only for patients with a specific biomarker.

Cancer clinical practice has also been revolutionized. For example, the 228,000 patients 25 who were expected to be diagnosed with non-small cell lung cancer (NSCLC) in the United States in 2020 are candidates for clinical next-generation sequencing (NGS) A c c e p t e d M a n u s c r i p t assays. These assays provide comprehensive mutation profiling, typically a panel of approximately 300 to 500 genes and the presence of a mutation or biomarker determines the therapy a patient will receive. Approximately 30% of patients with NSCLC will have a mutation in the genes EGFR (15%), 26 ALK (5%), 27 ROS1 (2%), 28 BRAF (5%), 29 and NTRK (<1%), 30 making them candidates for treatment with a targeted therapy. Approximately 50% 31 of patients with NSCLC will express programmed death ligand 1 (PD-L1) and are candidates for pembrolizumab. In the United States alone, approximately 100,000 patients with NSCLC will be treated with pembrolizumab in 2020, and at an average cost per dose of $10,000 32 the implication for health systems is substantial.

pharmacists have been integral to implementing cancer precision medicine, having led the development of molecular tumor boards 33, 34 and precision medicine services. 35 In addition, many oncology pharmacists are joining precision medicine teams and developing additional roles, including serving as a medication resource, facilitating interactions with pharmaceutical companies for drug assistance and specialty pharmacies for dispensing, and providing direct patient care to patients receiving precision medicine-based therapies. 36 Pharmacists have also implemented pharmacogenomic dose adjustment services for pertinent oncology germline drug-gene pairs like fluorouracil and DPYD, 37 approved in the last 10 years and all but one were targeted therapies, 41 with the majority of drugs in development being either cell based, checkpoint inhibitors, or targeted therapies. 42 Increased demand and increased personalization is expected to drive cancer care for the foreseeable future, and oncology pharmacists are needed to deliver this care. 43 Specialty pharmacy practitioners should also consider an expanded role in cancertargeted precision medicine, as their expertise is particularly important in meeting the needs of patients undergoing gene and cell-based therapies. Many of these products require careful and precise storage, distribution, and monitoring-processes specialty pharmacists are comfortable assuring. Patient adherence is important in many areas of therapeutics, but lack of adherence is particularly challenging and wasteful when products are complex, costly, and inconsistently reimbursed; again, these are therapeutic issues specialty pharmacy practitioners deal with often. Many therapies guided by precision medicine accompany other treatment components, and fragmenting gene or cell-based aspects of patient care from everything else individuals require will result in a higher risk of poor outcomes. Specialty pharmacy practitioners' ability to reduce fragmented care delivery will be critical in ensuring successful care of many patients.

Implications for health-system pharmacy. In several past ASHP Pharmacy In order for health-system pharmacy to establish a leadership position in precision medicine, pharmacists and pharmacy leaders must deepen their understanding of molecular diagnostics and therapeutics; must build new relationships with disciplines that they may not have worked with in the past, such as genetic counselors who help patients understand the implications of their genetic health; and must be prepared to venture into areas that are M a n u s c r i p t perhaps only peripherally related to medication management, such as in areas where genetic data suggest interventions other than medications. However, these challenges are all far easier to overcome for the pharmacy profession and pharmacy departments than for other disciplines and departments that are not as well positioned to meet the other requirements needed to successfully lead in precision medicine, as described above.

Pharmacists currently lead the development of guidelines for hereditary pharmacogenomic testing and were early implementers of hereditary pharmacogenomics into clinical practice. However, significant barriers to widespread implementation, including resources and logistics, remain. Current trends that potentially overcome these barriers include DTC and population-level genotyping, and pharmacist roles must continue to evolve with current trends. Somatic mutation testing in cancer has revolutionized cancer drug development and clinical care. Interdisciplinary teams, often led by pharmacists, have widely implemented cancer precision medicine initiatives. Given current deficits in the workforce of medical oncologists, the potential to expand oncology pharmacist roles is exponential, and specialty pharmacy practitioners are important partners. Health-system pharmacy should establish leadership roles in precision medicine.

A c c e p t e d M a n u s c r i p t

Committee on a Framework for Developing a New Taxonomy of Disease, National Research Council. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease

ASHP Foundation Pharmacy Forecast 2018: strategic planning advice for pharmacy departments in hospitals and health Systems

The Precision Medicine Initiative

The White House. Remarks by the president and the vice president at the 21st

Century Cures Act bill signing

ASHP statement on the pharmacist's role in clinical pharmacokinetic monitoring

Current practices in the delivery of pharmacogenomics: impact of the recommendations of the Pharmacy Practice Model Summit

Opportunities for pharmacists to integrate pharmacogenomics into clinical practice

Pharmacogenetics of opioids for the treatment of acute maternal pain during pregnancy and lactation

Codeine, ultrarapidmetabolism genotype, and postoperative death

Re: apnea in a child after oral codeine: a genetic variant -an ultra-rapid metabolizer

author's reply

More codeine fatalities after tonsillectomy in North American children

Codeine-associated pediatric deaths despite using recommended dosing guidelines: three case reports

The use of codeine and tramadol in the pediatric population-what is the verdict now?

Codeine: time to say

Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial

The dawn of consumer-directed testing

Physician experience with directto-consumer genetic testing in Kaiser Permanente

A model for genome-first care: returning secondary genomic findings to participants and their healthcare providers in a large research cohort

ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing

Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival

Cancer statistics

Front-line therapy in advanced non-small cell lung cancer with sensitive epidermal growth factor receptor mutations: a network meta-analysis

Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers

Targeted therapies for ROS1-rearranged non-small cell lung cancer

Targeting BRAF mutations in non-small cell lung cancer

Precision medicine becomes reality -tumor type-agnostic therapy

immunohistochemistry in non-small cell lung carcinoma

A phamacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive nonsmall cell lung cancer

Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine(R)) in cancer patients

A clinical pharmacy pilot within a precision medicine program for cancer patients and review of related pharmacist clinical practice

Precision medicine in oncology pharmacy practice

A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy

The state of cancer care in America

Supporting the future of the oncology workforce: ASCO medical student and trainee initiatives

Breast cancer drug approvals by the US FDA from

The global pipeline of cell therapies for cancer

Board-certified oncology pharmacists: their potential contribution to reducing a shortfall in oncology patient visits

A c c e p t e d M a n u s c r i p t